JP2019502902A5 - - Google Patents

Download PDF

Info

Publication number
JP2019502902A5
JP2019502902A5 JP2018525768A JP2018525768A JP2019502902A5 JP 2019502902 A5 JP2019502902 A5 JP 2019502902A5 JP 2018525768 A JP2018525768 A JP 2018525768A JP 2018525768 A JP2018525768 A JP 2018525768A JP 2019502902 A5 JP2019502902 A5 JP 2019502902A5
Authority
JP
Japan
Prior art keywords
pkd
patient
fluoro
sample
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018525768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502902A (ja
JP6895963B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/062075 external-priority patent/WO2017087409A1/en
Publication of JP2019502902A publication Critical patent/JP2019502902A/ja
Publication of JP2019502902A5 publication Critical patent/JP2019502902A5/ja
Application granted granted Critical
Publication of JP6895963B2 publication Critical patent/JP6895963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018525768A 2015-11-18 2016-11-15 多発性嚢胞腎のバイオマーカーおよびその使用 Active JP6895963B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257089P 2015-11-18 2015-11-18
US62/257,089 2015-11-18
PCT/US2016/062075 WO2017087409A1 (en) 2015-11-18 2016-11-15 Biomarker of polycystic kidney disease and uses thereof

Publications (3)

Publication Number Publication Date
JP2019502902A JP2019502902A (ja) 2019-01-31
JP2019502902A5 true JP2019502902A5 (https=) 2019-12-26
JP6895963B2 JP6895963B2 (ja) 2021-06-30

Family

ID=57539614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525768A Active JP6895963B2 (ja) 2015-11-18 2016-11-15 多発性嚢胞腎のバイオマーカーおよびその使用

Country Status (12)

Country Link
US (2) US11116755B2 (https=)
EP (1) EP3377908B1 (https=)
JP (1) JP6895963B2 (https=)
KR (1) KR20180083902A (https=)
CN (1) CN108700594B (https=)
AU (1) AU2016357720A1 (https=)
BR (1) BR112018009879A2 (https=)
CO (1) CO2018006126A2 (https=)
EA (1) EA201891170A1 (https=)
MX (1) MX2018006250A (https=)
WO (1) WO2017087409A1 (https=)
ZA (1) ZA201803035B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения
CN114040762A (zh) * 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용
JPWO2023145898A1 (https=) * 2022-01-27 2023-08-03

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710227B1 (en) 1998-09-16 2004-03-23 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
CA2256121A1 (en) 1998-06-08 1999-12-08 Hong Wang Cyclin-dependent kinase inhibitors as plant growth regulators
WO1999065910A1 (en) 1998-06-16 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fused azepinone cyclin dependent kinase inhibitors
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
KR100708573B1 (ko) 1999-05-24 2007-04-18 에이브이아이 바이오파마 인코포레이티드 다낭 신장 질환의 치료를 위한 ｃ-ｍｙｃ에 대한 안티센스
US6593356B2 (en) 1999-10-20 2003-07-15 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
EP1278749B1 (en) 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
EP1345941A1 (fr) 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
AU2002365211A1 (en) 2001-07-10 2003-09-02 Bristol-Myers Squibb Pharma Company 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
MY137843A (en) 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539163A (en) 2002-09-04 2007-03-30 Schering Corp Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497444C (en) 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
KR20050057139A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE378336T1 (de) 2002-09-19 2007-11-15 Schering Corp Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
AR041292A1 (es) 2002-09-19 2005-05-11 Schering Corp Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7186740B2 (en) 2002-09-23 2007-03-06 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
TW200413378A (en) 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
JP5661457B2 (ja) * 2007-06-06 2015-01-28 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 腎疾患の予測診断
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
US20120077263A1 (en) 2009-06-05 2012-03-29 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
CN102018702B (zh) 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
WO2011066352A1 (en) 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
WO2011084548A2 (en) * 2009-12-15 2011-07-14 King Faisal Specialist Hospital & Research Centre Methods and compositions for detecting recesssive familial fsgs and uses thereof
ES2606140T3 (es) 2010-10-01 2017-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
JP6021021B2 (ja) * 2010-11-05 2016-11-02 国立大学法人京都大学 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
KR20140072160A (ko) * 2011-10-03 2014-06-12 셀매틱스, 인크. 추정 자손에 대한 상태 발병 위험을 평가하는 방법 및 장치
WO2013059119A1 (en) 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN102590491B (zh) 2012-02-06 2014-12-10 中国人民解放军第三军医大学第一附属医院 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途
US10478446B2 (en) 2012-07-03 2019-11-19 Fondazione Centro San Raffaele Office Of Biotechnology Transfer Compounds for use in polycystic kidney disease
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2016022500A2 (en) 2014-08-04 2016-02-11 Genzyme Corporation Biomarkers of polycystic kidney disease and uses thereof
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения

Similar Documents

Publication Publication Date Title
US20250276066A1 (en) Methods, compositions and compounds for treating age-related diseases and conditions
JP2016519763A5 (https=)
Oh et al. Causes and evaluation of mildly elevated liver transaminase levels
JP2019502902A5 (https=)
RU2015144149A (ru) Протеомные маркеры илф
US12150938B2 (en) Biomarker of polycystic kidney disease and uses thereof
JP5274458B2 (ja) 黒色腫における治療応答のための早期指標としての黒色腫阻害性活性（ｍｉａ）タンパク質の使用
Wong et al. Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model
Thomas et al. Current role of anti-angiogenic strategies for glioblastoma
Yoshida et al. Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1
Zhao et al. Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway
JP2020170013A (ja) 多発性嚢胞腎のバイオマーカーおよびその使用
EP4051702A1 (en) Theranostics for hypertension induced myocardial microbleeds
JP2017525955A5 (https=)
Bozkurt et al. Is late recurrence a predictive clinical marker for better sunitinib response in metastatic renal cell carcinoma patients?
JP2023501500A (ja) ＯｘＰＬ関連の疾患及び障害を診断するための方法及び組成物
US20250170129A1 (en) Senotherapeutic agents and alpha-klotho polypeptides
Cho et al. Clinical usefulness of transarterial chemoembolization response prior to liver transplantation as predictor of optimal timing for living donor liver transplantation
Eathiraj et al. Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751
Huston et al. Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension
Inoue et al. INCIDENCE AND RISK FACTORS OF POSTOPERATIVE HYPERTENSION AFTER PARTIAL NEPHRECTOMY FOR RENAL TUMORS: MP49-07
Dicato Thrombosis in Cancer Patients
Migliorati Prevention and Treatment of Osteonecrosis
Shah et al. An MMP13-Selective Inhibitor Delays Primary Tumor Growth and the Onset of Tumor